US SEC Trading Suspension Halt Orders — September 10, 2026

Regained Nasdaq compliance on Sept 9, 2026, after filing delinquent 10-Q, removing immediate delisting risk. This is a clear positive catalyst for the stock, as the overhang of a potential suspension is gone.

Received a second Nasdaq deficiency notice (equity < $2.5M) on Sept 3, 2026, with reported equity of only $1.62M. This compounds an existing bid price deficiency, creating a dual-threat delisting scenario. The stock is a high-risk short candidate.

Received a Nasdaq deficiency letter on Sept 8, 2026, for equity non-compliance, but was granted an extension to Nov 25, 2026, after submitting plans including a $5M public offering. The stock's survival hinges on successful capital raise; failure means delisting.

Announced voluntary closure and liquidation, with shares ceasing to trade on NYSE Arca on Oct 15, 2026. This is a complete fund shutdown, offering no secondary market after the halt. Investors should exit before the Oct 15 deadline to avoid forced liquidation.

Voluntarily delisting from NYSE to TXSE, effective Oct 2, 2026. No change in ticker or business operations. This is a neutral event but may create a temporary liquidity discount for investors unfamiliar with TXSE.

Voluntarily delisting common units and Series I Preferred from NYSE to TXSE, effective Oct 2, 2026. Tickers (ET, ETprI) unchanged. Preferred holders should note the exchange change but no impact on distributions.

Voluntarily delisting from NYSE to TXSE, effective Oct 2, 2026. Ticker unchanged. The move is seamless but may reduce institutional visibility.

Voluntarily delisting from NYSE to TXSE, effective Oct 2, 2026. Ticker unchanged. This is a pure listing transfer with no financial impact.

Received a second Nasdaq deficiency notice on Sept 3, 2026, for equity < $2.5M (actual: $1.62M). Already under a bid price deficiency with a Jan 13, 2027 deadline. Failure to resolve equity issue will also block a second bid price extension, making delisting highly probable.

Received Nasdaq deficiency letter on Sept 8, 2026, for equity < $2.5M. Granted extension to Nov 25, 2026, but the company warns there is no assurance of regaining compliance. The planned $5M public offering may fail or be dilutive.

The fund is shutting down entirely. Shares will cease trading on Oct 15, 2026, and will be liquidated by Oct 22, 2026. Investors holding after Oct 15 will have no liquidity and will receive cash proceeds, potentially at a discount to NAV.

While compliance was regained on Sept 9, 2026, the company had a prior delinquency for its 10-Q filing. This indicates potential internal control or reporting weaknesses that could recur.

Voluntary delisting from NYSE to TXSE may reduce liquidity and institutional coverage, as TXSE is a new, less liquid exchange. Investors may face wider bid-ask spreads.

The transfer of both common and preferred units to TXSE could create confusion among preferred holders, who may be less familiar with the new exchange.

Delisting from NYSE may reduce the company's profile among institutional investors and index funds, potentially leading to selling pressure.

As a smaller entity, moving to TXSE may further reduce its visibility and trading volume.

The stock is now compliant with Nasdaq listing rules after filing its 10-Q. This removes a major overhang, and the stock may re-rate as the risk of suspension is eliminated.

The fund will liquidate by Oct 22, 2026. If the ETF trades at a discount to NAV before the halt on Oct 15, investors could buy and capture the NAV at liquidation. Monitor for discount widening.

With a dual deficiency and high delisting risk, the stock may be heavily shorted. Any positive news (e.g., capital injection, reverse split) could trigger a short squeeze.

If the company successfully completes its $5M public offering by the Nov 25, 2026 deadline, it could regain compliance and avoid delisting. This is a high-risk, high-reward event-driven play.

The Series I Preferred units are transferring to TXSE with no change in terms. If the market overreacts and sells off due to exchange migration, it could create a yield opportunity for patient investors.

The voluntary delisting may be part of a broader strategy to optimize tax or regulatory structure. If the move reduces costs, it could be accretive to unitholders over time.

The delisting is voluntary and not due to any failure. The ticker remains unchanged, so the transition should be smooth. Any dip in price due to exchange change could be a buying opportunity.

The delisting is purely administrative. With no financial impact, the stock should trade normally. Any irrational sell-off is a buying opportunity.

Four energy MLPs/partnerships (SUN, ET-PI, USAC, SUNC) are voluntarily delisting from NYSE to TXSE in a coordinated move, all effective Oct 2-5, 2026. This suggests a sector-wide preference for a regional exchange, possibly for lower fees, regulatory alignment, or a pro-energy business environment. Implications: Reduced liquidity and institutional coverage for these names, but no fundamental change in operations.

Two micro-cap life sciences companies (AIDX, ISPC) received Nasdaq deficiency notices for failing to meet the $2.5M stockholders' equity requirement. This highlights a sector-wide struggle for small-cap biotechs to maintain listing standards amid a tight capital market. Implications: Expect more delistings or reverse splits in the sector.

The voluntary liquidation of the Bitwise Dogecoin ETF (BWOW) is a bearish signal for crypto-themed ETFs, particularly those tied to meme coins. This suggests low investor interest and high operational costs. Implications: Other single-asset crypto ETFs may face similar closures.

While GITS resolved its delinquency, AIDX and ISPC face escalating risks. This creates a clear divergence: companies with access to capital (GITS) can survive, while those without (AIDX, ISPC) are on the brink. Implications: Investors should favor companies with strong balance sheets and access to funding.

Of the eight filings, four are voluntary delistings (SUN, ET-PI, USAC, SUNC), one is a voluntary liquidation (BWOW), and only three involve regulatory compliance issues (GITS, AIDX, ISPC). This suggests that proactive exchange migration is a growing trend, while regulatory suspensions are concentrated in micro-cap names.

Must resolve equity deficiency by Jan 13, 2027, or face delisting. Watch for any capital raise, reverse split, or merger announcement. [Deadline: Jan 13, 2027]

Must evidence compliance by Nov 25, 2026. Watch for completion of the $5M public offering and any updates on stockholders' equity. [Deadline: Nov 25, 2026]

Shares cease trading on Oct 15, 2026, with liquidation by Oct 22, 2026. Monitor for any NAV discount arbitrage opportunities. [Deadlines: Oct 15 & Oct 22, 2026]

Trading on TXSE begins Oct 5, 2026. Watch for initial trading volume and liquidity compared to NYSE. [Date: Oct 5, 2026]

Series I Preferred units transfer to TXSE on Oct 5, 2026. Monitor for any unusual price action or distribution announcements. [Date: Oct 5, 2026]

Watch for any volume or price dislocation after the Oct 5 TXSE listing. [Date: Oct 5, 2026]

After regaining compliance, watch for timely filing of the next quarterly report to avoid recurrence of delinquency. [Next filing: Q3 2026]

Monitor for any liquidity issues or ticker confusion post-transfer. [Date: Oct 5, 2026]